Table of Contents Author Guidelines Submit a Manuscript
Erratum

An erratum for this article has been published. To view the erratum, please click here.

Journal of Thyroid Research
Volume 2011 (2011), Article ID 856050, 8 pages
http://dx.doi.org/10.4061/2011/856050
Research Article

Cell-Type-Dependent Thyroid Hormone Effects on Glioma Tumor Cell Lines

1Department of Pharmacology, University of Athens, 75 Mikras Asias Avenue,11527 Goudi, Athens, Greece
2School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston PR1 2HE, Lancashire, UK

Received 5 August 2011; Revised 24 September 2011; Accepted 24 September 2011

Academic Editor: Fausto Bogazzi

Copyright © 2011 Liappas Alexandros et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. Mourouzis, F. Forini, C. Pantos et al., “Thyroid hormone and cardiac disease: from basic concepts to clinical application,” Journal of Thyroid Research. In press.
  2. C. Pantos, I. Mourouzis, C. Xinaris, Z. Papadopoulou-Daifoti, and D. Cokkinos, “Thyroid hormone and “cardiac metamorphosis”: potential therapeutic implications,” Pharmacology and Therapeutics, vol. 118, no. 2, pp. 277–294, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Aranda, O. Martínez-Iglesias, L. Ruiz-Llorente, V. García-Carpizo, and A. Zambrano, “Thyroid receptor: roles in cancer,” Trends in Endocrinology and Metabolism, vol. 20, no. 7, pp. 318–324, 2009. View at Publisher · View at Google Scholar
  4. J. M. Gonzalez-Sancho, V. Garcia, F. Bonilla et al., “Thyroid hormone receptors/THR genes in human cancer,” Cancer Letters, vol. 192, no. 2, pp. 121–132, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Garcia-Silva and A. Aranda, “The thyroid hormone receptor is a suppressor of ras-mediated transcription, proliferation, and transformation,” Molecular and Cellular Biology, vol. 24, no. 17, pp. 7514–7523, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. O. Martínez-Iglesias, S. García-Silva, J. Regadera, and A. Aranda, “Hypothyroidism enhances tumor invasiveness and metastasis development,” PLoS ONE, vol. 4, no. 7, article e6428, 2009. View at Publisher · View at Google Scholar
  7. G. Beatson, “On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases,” The Lancet, vol. 148, no. 3802, pp. 101–107, 1896. View at Google Scholar · View at Scopus
  8. A. A. Loeser, “A new therapy for prevention of post-operative recurrences in genital and breast cancer; a six-years study of prophylactic thyroid treatment,” British Medical Journal, vol. 2, no. 4901, pp. 1380–1383, 1954. View at Google Scholar
  9. H. Ohgaki, “Epidemiology of brain tumors,” Methods in Molecular Biology, vol. 472, pp. 323–342, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Nauman, W. Bonicki, R. Michalik, A. Warzecha, and Z. Czernicki, “The concentration of thyroid hormones and activities of iodothyronine deiodinases are altered in human brain gliomas,” Folia Neuropathologica, vol. 42, no. 2, pp. 67–73, 2004. View at Google Scholar · View at Scopus
  11. F. B. Davis, H. Y. Tang, A. Shih et al., “Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells,” Cancer Research, vol. 66, no. 14, pp. 7270–7275, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Y. Lin, M. Sun, H. Y. Tang et al., “L-thyroxine vs. 3,5,3-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase,” American Journal of Physiology, vol. 296, no. 5, pp. C980–C991, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Y. Lin, H. Y. Tang, T. Keating et al., “Resveratrol is pro-apoptotic and thyroid hormone is anti-apoptotic in glioma cells: both actions are integrin and ERK mediated,” Carcinogenesis, vol. 29, no. 1, pp. 62–69, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Pantos, I. Mourouzis, and D. V. Cokkinos, “Rebuilding the post-infarcted myocardium by activating “physiologic” hypertrophic signaling pathways: the thyroid hormone paradigm,” Heart Failure Reviews, vol. 15, no. 2, pp. 143–154, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Pantos, I. Mourouzis, T. Saranteas et al., “Acute T3 treatment protects the heart against ischemia-reperfusion injury via TRα1 receptor,” Molecular and Cellular Biochemistry, vol. 353, no. 1-2, pp. 235–241, 2011. View at Publisher · View at Google Scholar
  16. A. Shulga, A. Blaesse, K. Kysenius et al., “Thyroxin regulates BDNF expression to promote survival of injured neurons,” Molecular and Cellular Neuroscience, vol. 42, no. 4, pp. 408–418, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. E. Kress, J. Samarut, and M. Plateroti, “Thyroid hormones and the control of cell proliferation or cell differentiation: paradox or duality?” Molecular and Cellular Endocrinology, vol. 313, no. 1-2, pp. 36–49, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Bedo, A. Pascual, and A. Aranda, “Early thyroid hormone-induced gene expression changes in N2a-beta neuroblastoma cells,” Journal of Molecular Neuroscience, vol. 45, no. 2, pp. 76–86, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Perra, M. A. Kowalik, M. Pibiri, G. M. Ledda-Columbano, and A. Columbano, “Thyroid hormone receptor ligands induce regression of rat preneoplastic liver lesions causing their reversion to a differentiated phenotype,” Hepatology, vol. 49, no. 4, pp. 1287–1296, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Pantos, I. Mourouzis, G. Galanopoulos et al., “Thyroid hormone receptor 1 downregulation in postischemic heart failure progression: the potential role of tissue hypothyroidism,” Hormone and Metabolic Research, vol. 42, no. 10, pp. 718–724, 2010. View at Publisher · View at Google Scholar
  21. C. Pantos, C. Xinaris, I. Mourouzis et al., “Thyroid hormone receptor α1: a switch to cardiac cell “metamorphosis”?” Journal of Physiology and Pharmacology, vol. 59, no. 2, pp. 253–269, 2008. View at Google Scholar
  22. J. Zhang and M. A. Lazar, “The mechanism of action of thyroid hormones,” Annual Review of Physiology, vol. 62, pp. 439–466, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. W. H. Chappell, L. S. Steelman, J. M. Long et al., “Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health,” Oncotarget, vol. 2, no. 3, pp. 135–164, 2011. View at Google Scholar
  24. I. Hers, E. E. Vincent, and J. M. Tavaré, “Akt signalling in health and disease,” Cellular Signalling, vol. 23, no. 10, pp. 1515–1527, 2011. View at Publisher · View at Google Scholar
  25. H. W. Lo, “Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas,” Current Cancer Drug Targets, vol. 10, no. 8, pp. 840–848, 2011. View at Google Scholar
  26. I. F. Pollack, R. L. Hamilton, P. C. Burger et al., “Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the Children's Oncology Group,” Journal of Neuro-Oncology, vol. 99, no. 2, pp. 155–163, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. Q. W. Fan, C. Cheng, C. Hackett et al., “Akt and autophagy cooperate to promote survival of drug-resistant glioma,” Science Signaling, vol. 3, no. 147, article ra81, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. E. A. El-Habr, P. Tsiorva, M. Theodorou et al., “Analysis of PIK3CA and B-RAF gene mutations in human astrocytomas: association with activation of ERK and AKT,” Clinical Neuropathology, vol. 29, no. 4, pp. 239–245, 2010. View at Google Scholar · View at Scopus
  29. J. P. Robinson, M. W. VanBrocklin, K. J. Lastwika, A. J. McKinney, S. Brandner, and S. L. Holmen, “Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo,” Oncogene, vol. 30, no. 11, pp. 1341–1350, 2011. View at Publisher · View at Google Scholar · View at Scopus